Title
Utility of self-reported sleep disturbances as a marker for major depressive disorder (MDD): Findings from the World Mental Health Japan Survey 2002-2006
Date Issued
30 June 2012
Access level
open access
Resource Type
journal article
Author(s)
Ando S.
Kawakami N.
Abstract
Although major depressive disorder (MDD) is a serious common disease, many depressive patients seek primary care with complaints of sleep disturbances that remain undiagnosed. The purpose of this study was to investigate the utility of self-reported sleep disturbances as a marker for MDD. This study investigated the association between 12-month prevalence of self-reported sleep disturbances and MDD using data from a cross-sectional survey in Japan. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and the area under the receiver operating characteristic curve (AUC) of self-reported sleep disturbances as a marker for MDD were 58.9%, 73.4%, 6.9%, 98.1%, and 0.66, respectively. Self-reported sleep disturbances showed highest utility for the youngest group. Among four types of sleep disturbances, the problem of daytime sleepiness was most useful as a marker for MDD. Combined with at least moderate role impairment, self-reported sleep disturbances became more informative with higher specificity (99.6%) and PPV (80.0%) as a marker for MDD. Self-reported sleep disturbances cannot be a marker for MDD in isolation. Comorbid role impairment increases the probability of MDD. Clinicians should be cautious in assessments of young people who have sleep disturbances. Daytime sleepiness should be included among the questions asked when inquiring about sleep disturbances. © 2012 Elsevier Ltd.
Start page
146
End page
153
Volume
198
Issue
1
Language
English
OCDE Knowledge area
Psiquiatría Medicina clínica
Scopus EID
2-s2.0-84867142570
PubMed ID
Source
Psychiatry Research
ISSN of the container
18727123
Sponsor(s)
We appreciate the staff members and other field coordinators in the WMH-J 2002–2006 Survey. The WMH-J 2002–2006 Survey was carried out in conjunction with the World Health Organization World Mental Health (WMH) Survey Initiative. The World Mental Health Japan (WMH-J) was supported by the grant for Research on Psychiatric and Neurological Diseases and Mental Health ( H13-SHOGAI-023 , H14-TOKUBETSU-026 , H16-KOKORO-013 ) from the Japan Ministry of Health, Labour, and Welfare . We would like to thank staff members, filed coordinators, and interviewers of the WMH Japan 2002–2004 Survey. The WMH Japan 2002–2004 Survey was carried out in conjunction with the World Health Organization World Mental Health (WMH) Survey Initiative. We also thank the WMH staff for assistance with instrumentation, fieldwork, and data analysis. These activities were supported by the US National Institute of Mental Health ( R01MH070884 ), the John D. and Catherine T. MacArthur Foundation , the Pfizer Foundation , the US Public Health Service ( R13-MH066849 , R01-MH069864 , and R01 DA016558 ), the Fogarty International Center (FIRCA R01-TW006481 ), the Pan American Health Organization , Eli Lilly and Company , Ortho-McNeil Pharmaceutical, Inc. , GlaxoSmithKline , and Bristol-Myers Squibb . A complete list of WMH publications can be found at http://www.hcp.med.harvard.edu/wmh/ . SA is funded through unrestricted scholarship of The GlaxoSmithKline International Scholarship Charitable Trust Fund.
Sources of information: Directorio de Producción Científica Scopus